N-(3-(4-carbamoylphenoxy)-5-(4-fluorophenoxy)phenyl)-4-(2-ethylbutyl)-4-hydroxypiperidine-1-carboxamide

ID: ALA3401383

Chembl Id: CHEMBL3401383

PubChem CID: 89484779

Max Phase: Preclinical

Molecular Formula: C31H36FN3O5

Molecular Weight: 549.64

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CCC(CC)CC1(O)CCN(C(=O)Nc2cc(Oc3ccc(F)cc3)cc(Oc3ccc(C(N)=O)cc3)c2)CC1

Standard InChI:  InChI=1S/C31H36FN3O5/c1-3-21(4-2)20-31(38)13-15-35(16-14-31)30(37)34-24-17-27(39-25-9-5-22(6-10-25)29(33)36)19-28(18-24)40-26-11-7-23(32)8-12-26/h5-12,17-19,21,38H,3-4,13-16,20H2,1-2H3,(H2,33,36)(H,34,37)

Standard InChI Key:  XWGOCGLJLLJAOE-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA3401383

   N-[3-(4-carbamoylphenoxy)-5-(4-fluorophenoxy)phenyl]-4-(2-ethylbutyl)-4-hydroxypiperidine-1-carboxamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 549.64

Molecular Weight (Monoisotopic): 549.2639

AlogP: 6.69

#Rotatable Bonds: 10

Polar Surface Area: 114.12

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: 2

HBA (Lipinski): 8

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 12.63

CX Basic pKa: ┄

CX LogP: 5.06

CX LogD: 5.06

Aromatic Rings: 3

Heavy Atoms: 40

QED Weighted: 0.26

Np Likeness Score: -0.89

References

1. Kusumi K, Shinozaki K, Kanaji T, Kurata H, Naganawa A, Otsuki K, Matsushita T, Sekiguchi T, Kakuuchi A, Seko T..  (2015)  Discovery of novel S1P2 antagonists. Part 1: discovery of 1,3-bis(aryloxy)benzene derivatives.,  25  (7): [PMID:25746814] [10.1016/j.bmcl.2015.02.029]

2. Kusumi K, Shinozaki K, Yamaura Y, Hashimoto A, Kurata H, Naganawa A, Ueda H, Otsuki K, Matsushita T, Sekiguchi T, Kakuuchi A, Seko T..  (2015)  Discovery of novel S1P2 antagonists. Part 2: Improving the profile of a series of 1,3-bis(aryloxy)benzene derivatives.,  25  (20): [PMID:26384288] [10.1016/j.bmcl.2015.09.022]

3. Luo D, Liu X, Jiang L, Guo Z, Lv Y, Tian X, Wang X, Cui S, Wan S, Qu X, Xu X, Li X..  (2022)  Rational Design, Synthesis, and Biological Evaluation of Novel S1PR2 Antagonists for Reversing 5-FU-Resistance in Colorectal Cancer.,  65  (21.0): [PMID:36269639] [10.1021/acs.jmedchem.2c00958]

Source

Source(1):

• Scientific Literature